Free Trial
→ Read now. Do not delete. You’ve been warned. (From Porter & Company) (Ad)tc pixel Free IZTC Stock Alerts

Invizyne Technologies (IZTC) Competitors

Invizyne Technologies logo
$9.92 +0.52 (+5.53%)
As of 05/22/2026
Compare

IZTC vs. RNAC, NERV, CHRS, SGMT, and FHTX

Should you buy Invizyne Technologies stock or one of its competitors? MarketBeat compares Invizyne Technologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Invizyne Technologies include Cartesian Therapeutics (RNAC), Minerva Neurosciences (NERV), Coherus Oncology (CHRS), Sagimet Biosciences (SGMT), and Foghorn Therapeutics (FHTX). These companies are all part of the "pharmaceutical products" industry.

How does Invizyne Technologies compare to Cartesian Therapeutics?

Invizyne Technologies (NASDAQ:IZTC) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

In the previous week, Cartesian Therapeutics had 1 more articles in the media than Invizyne Technologies. MarketBeat recorded 1 mentions for Cartesian Therapeutics and 0 mentions for Invizyne Technologies. Invizyne Technologies' average media sentiment score of 0.00 equaled Cartesian Therapeutics'average media sentiment score.

Company Overall Sentiment
Invizyne Technologies Neutral
Cartesian Therapeutics Neutral

87.0% of Cartesian Therapeutics shares are owned by institutional investors. 37.2% of Cartesian Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Cartesian Therapeutics has a consensus price target of $33.00, suggesting a potential upside of 388.89%. Given Cartesian Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Cartesian Therapeutics is more favorable than Invizyne Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Invizyne Technologies
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Cartesian Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67

Invizyne Technologies has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%.

Company Net Margins Return on Equity Return on Assets
Invizyne TechnologiesN/A N/A N/A
Cartesian Therapeutics -8,550.65%N/A -28.25%

Invizyne Technologies has higher earnings, but lower revenue than Cartesian Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Invizyne TechnologiesN/AN/AN/AN/AN/A
Cartesian Therapeutics$2.80M70.83-$130.30M-$5.90N/A

Summary

Cartesian Therapeutics beats Invizyne Technologies on 7 of the 9 factors compared between the two stocks.

How does Invizyne Technologies compare to Minerva Neurosciences?

Invizyne Technologies (NASDAQ:IZTC) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

Minerva Neurosciences has a consensus target price of $10.50, suggesting a potential upside of 99.62%. Given Minerva Neurosciences' stronger consensus rating and higher probable upside, analysts clearly believe Minerva Neurosciences is more favorable than Invizyne Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Invizyne Technologies
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Minerva Neurosciences
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Minerva Neurosciences had 10 more articles in the media than Invizyne Technologies. MarketBeat recorded 10 mentions for Minerva Neurosciences and 0 mentions for Invizyne Technologies. Minerva Neurosciences' average media sentiment score of 0.74 beat Invizyne Technologies' score of 0.00 indicating that Minerva Neurosciences is being referred to more favorably in the news media.

Company Overall Sentiment
Invizyne Technologies Neutral
Minerva Neurosciences Positive

Company Net Margins Return on Equity Return on Assets
Invizyne TechnologiesN/A N/A N/A
Minerva Neurosciences N/A N/A -32.63%

34.6% of Minerva Neurosciences shares are owned by institutional investors. 10.4% of Minerva Neurosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Invizyne TechnologiesN/AN/AN/AN/AN/A
Minerva NeurosciencesN/AN/A-$293.42M-$29.16N/A

Summary

Minerva Neurosciences beats Invizyne Technologies on 7 of the 8 factors compared between the two stocks.

How does Invizyne Technologies compare to Coherus Oncology?

Invizyne Technologies (NASDAQ:IZTC) and Coherus Oncology (NASDAQ:CHRS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and valuation.

Coherus Oncology has higher revenue and earnings than Invizyne Technologies.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Invizyne TechnologiesN/AN/AN/AN/AN/A
Coherus Oncology$42.17M5.89$168.02M$1.670.96

In the previous week, Invizyne Technologies' average media sentiment score of 0.00 equaled Coherus Oncology'saverage media sentiment score.

Company Overall Sentiment
Invizyne Technologies Neutral
Coherus Oncology Neutral

72.8% of Coherus Oncology shares are owned by institutional investors. 8.1% of Coherus Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Coherus Oncology has a consensus target price of $8.67, indicating a potential upside of 438.30%. Given Coherus Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Coherus Oncology is more favorable than Invizyne Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Invizyne Technologies
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Coherus Oncology
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75

Coherus Oncology has a net margin of 397.30% compared to Invizyne Technologies' net margin of 0.00%. Invizyne Technologies' return on equity of 0.00% beat Coherus Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
Invizyne TechnologiesN/A N/A N/A
Coherus Oncology 397.30%-198.90%-46.65%

Summary

Coherus Oncology beats Invizyne Technologies on 7 of the 9 factors compared between the two stocks.

How does Invizyne Technologies compare to Sagimet Biosciences?

Sagimet Biosciences (NASDAQ:SGMT) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends and analyst recommendations.

In the previous week, Sagimet Biosciences had 3 more articles in the media than Invizyne Technologies. MarketBeat recorded 3 mentions for Sagimet Biosciences and 0 mentions for Invizyne Technologies. Sagimet Biosciences' average media sentiment score of 0.15 beat Invizyne Technologies' score of 0.00 indicating that Sagimet Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
Sagimet Biosciences Neutral
Invizyne Technologies Neutral

Invizyne Technologies has lower revenue, but higher earnings than Sagimet Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sagimet Biosciences$2M115.50-$51.04M-$1.34N/A
Invizyne TechnologiesN/AN/AN/AN/AN/A

Invizyne Technologies' return on equity of 0.00% beat Sagimet Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Sagimet BiosciencesN/A -37.57% -35.52%
Invizyne Technologies N/A N/A N/A

Sagimet Biosciences presently has a consensus price target of $25.75, indicating a potential upside of 263.19%. Given Sagimet Biosciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Sagimet Biosciences is more favorable than Invizyne Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sagimet Biosciences
1 Sell rating(s)
2 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.67
Invizyne Technologies
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

87.9% of Sagimet Biosciences shares are owned by institutional investors. 14.7% of Sagimet Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Sagimet Biosciences beats Invizyne Technologies on 8 of the 10 factors compared between the two stocks.

How does Invizyne Technologies compare to Foghorn Therapeutics?

Invizyne Technologies (NASDAQ:IZTC) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings.

61.6% of Foghorn Therapeutics shares are owned by institutional investors. 7.6% of Foghorn Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Invizyne Technologies has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -266.88%.

Company Net Margins Return on Equity Return on Assets
Invizyne TechnologiesN/A N/A N/A
Foghorn Therapeutics -266.88%N/A -35.38%

Invizyne Technologies has higher earnings, but lower revenue than Foghorn Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Invizyne TechnologiesN/AN/AN/AN/AN/A
Foghorn Therapeutics$30.91M8.02-$74.28M-$1.16N/A

In the previous week, Foghorn Therapeutics had 2 more articles in the media than Invizyne Technologies. MarketBeat recorded 2 mentions for Foghorn Therapeutics and 0 mentions for Invizyne Technologies. Foghorn Therapeutics' average media sentiment score of 0.28 beat Invizyne Technologies' score of 0.00 indicating that Foghorn Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Invizyne Technologies Neutral
Foghorn Therapeutics Neutral

Foghorn Therapeutics has a consensus target price of $11.43, suggesting a potential upside of 170.82%. Given Foghorn Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Foghorn Therapeutics is more favorable than Invizyne Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Invizyne Technologies
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Foghorn Therapeutics
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.88

Summary

Foghorn Therapeutics beats Invizyne Technologies on 9 of the 11 factors compared between the two stocks.

Get Invizyne Technologies News Delivered to You Automatically

Sign up to receive the latest news and ratings for IZTC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IZTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IZTC vs. The Competition

Export
MetricInvizyne TechnologiesBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$62.02M$309.61M$6.46B$12.34B
Dividend YieldN/AN/A2.76%5.28%
P/E RatioN/AN/A21.2225.65
Price / SalesN/A189.70553.9286.28
Price / CashN/A22.4443.4956.67
Price / BookN/A4.7710.377.14
Net IncomeN/A-$132.96M$3.57B$335.98M
7 Day Performance3.87%2.45%6.40%4.15%
1 Month Performance-3.78%31.23%3.52%2.54%
1 Year Performance-33.42%77.59%34.02%35.05%

Invizyne Technologies Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IZTC
Invizyne Technologies
N/A$9.92
+5.5%		N/A-33.4%$62.02MN/AN/A29
RNAC
Cartesian Therapeutics
2.6296 of 5 stars		$7.38
-10.8%		$33.00
+347.2%		-26.3%$242.99M$2.80MN/A64
NERV
Minerva Neurosciences
2.6001 of 5 stars		$5.21
-5.3%		$10.50
+101.5%		+260.3%$242.73MN/AN/A9
CHRS
Coherus Oncology
2.5633 of 5 stars		$1.57
-3.7%		$8.67
+452.0%		+112.9%$242.17M$46.88M0.94330
SGMT
Sagimet Biosciences
3.0953 of 5 stars		$6.90
-6.4%		$28.63
+314.9%		+105.5%$240.15M$2MN/A8

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:IZTC) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
Trump Admin to Pump $1 Billion into this “Off-the-Radar” AI Stock
The U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...
InvestorPlace | Sponsoredtc pixel
The S-1 just dropped. 22 days left.
The SpaceX S-1 is now public - $18.7 billion in revenue, a $75 billion raise, and a June 12 Nasdaq listing con...
Behind the Markets | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel
Your book attached
Bill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...
Profits Run | Sponsoredtc pixel
Gold surged 600 dollars last time this indicator peaked
The Buffett Indicator has predicted every major gold bull run this century - 2000, 2008, and 2020, when gold s...
Porter & Company | Sponsoredtc pixel
Opportunity Forming in a U.S. Supply-Chain Weak Spot?
America has a supply-chain problem with graphite - demand is climbing while dependence on foreign sources rema...
i2i Marketing Group, LLC | Sponsoredtc pixel